Teva Jumps Most in Two Weeks on FDA Clearance of Cancer Drug

Feb. 29 (Bloomberg) -- Teva Pharmaceutical Industries Ltd. jumped the most in two weeks after its Pharmachemie BV unit was approved by the U.S. Food & Drug Administration to sell preservative-free methotrexate, a treatment for cancer.

The shares advanced 2.2 percent, the biggest intraday gain since Feb. 15, to 170.40 shekels at 12:39 p.m. in Tel Aviv.

To contact the reporter on this story: Gwen Ackerman in Jerusalem at gackerman@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net